Activated Protein C Inhibits Local Coagulation after Intrapulmonary Delivery of Endotoxin in Humans
- 15 May 2005
- journal article
- clinical trial
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 171 (10), 1125-1128
- https://doi.org/10.1164/rccm.200411-1483oc
Abstract
Rationale: Acute lung injury and pneumonia are associated with pulmonary activation of coagulation and suppression of fibrinolysis, resulting in fibrin deposition in the lung. Activated protein C (APC) has systemic anticoagulant effects in patients with sepsis. Objective: To determine the effect of systemic administration of recombinant human APC on endotoxin-induced hemostatic alterations in the bronchoalveolar space in humans. Methods: Healthy humans received intravenous APC (24 μg/kg/hour; n = 8) or vehicle (n = 7); all subjects were administered saline in one lung subsegment and endotoxin (4 ng/kg) into the contralateral lung. Bronchoalveolar lavage was performed 16 hours after saline and endotoxin administration. Measurements and Main Results: Endotoxin induced local activation of coagulation, as reflected by elevated levels of thrombin–antithrombin complexes (1.9 ± 0.1 ng/ml) and soluble tissue factor (15.0 ± 0.6 pg/ml) in bronchoalveolar lavage fluid, which was inhibited by APC (1.4 ± 0.1 ng/ml and 12.3 ± 0.4 pg/ml, respectively; both p < 0.01). Concurrently, endotoxin suppressed fibrinolysis, as indicated by reduced bronchoalveolar levels of plasminogen activator activity accompanied by elevated levels of plasminogen activator inhibitor type I activity. APC diminished the rise in plasminogen activator inhibitor type I activity (from 3.9 ± 0.1 to 3.0 ± 0.2 ng/ml, p = 0.002), while not significantly influencing plasminogen activator activity levels. Endotoxin reduced bronchoalveolar protein C concentrations, which was prevented by APC. Protein C did not influence the endotoxin-induced rise in local soluble thrombomodulin levels. Conclusion: APC exerts an anticoagulant effect in the human lung challenged with endotoxin.Keywords
This publication has 38 references indexed in Scilit:
- Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxisBlood, 2004
- Activated protein C in sepsisJournal of Thrombosis and Haemostasis, 2004
- Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in miceBlood, 2004
- Effects of Drotrecogin Alfa (Activated) in Human EndotoxemiaShock, 2004
- Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumoniaThorax, 2004
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisCritical Care Medicine, 2003
- Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsisThrombosis and Haemostasis, 2003
- Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent mannerFEBS Letters, 2000
- Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unitBritish Journal of Haematology, 1990
- Promotion and Subsequent Inhibition of Plasminogen Activation after Administration of Intravenous Endotoxin to Normal SubjectsNew England Journal of Medicine, 1989